Status:

COMPLETED

Eltrombopag for Post Transplant Thrombocytopenia

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborating Sponsors:

Novartis Pharmaceuticals

Conditions:

Thrombocytopenia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The goal of this clinical research study is to learn if eltrombopag can help to improve platelet counts in patients with low platelets after they have had a stem cell transplant. The safety of this dr...

Detailed Description

The Study Drug: Platelets are cells that help the blood clot. Platelet counts are often lower after receiving a stem cell transplant. When the number of platelets in your body gets too low, it can ca...

Eligibility Criteria

Inclusion

  • Patients \>/= 35 days post HCT with Platelet count \</= 20 x 10\^9/l sustained for 7 days or patients are platelet transfusion dependent, and
  • Neutrophil count \>/= 1.5 x 10\^9/l anytime within the last seven days before enrollment. Patients can be on myeloid or erythroid growth factors for example filgrastim), and
  • Age \>/= 18

Exclusion

  • Recurrence or progression of primary malignancy after HCT
  • ALT \>/= 2.5 times the ULN
  • Serum bilirubin \>2mg/dl (unless due to Gilbert's syndrome)
  • Documented deep vein thrombosis within 1 year before enrollment on the study, except if upper arm thrombosis related to central venous catheters, within 3 months before enrollment on the study.
  • ECOG Performance status \>2
  • Pregnancy: Women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation. A woman of child-bearing potential is defined as a woman who has not been naturally post-menopausal for at least 12 consecutive months or with no previous surgical sterilization. A negative pregnancy test result will be required before any study drug is given.

Key Trial Info

Start Date :

February 17 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 4 2018

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT01000051

Start Date

February 17 2010

End Date

April 4 2018

Last Update

September 18 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Eltrombopag for Post Transplant Thrombocytopenia | DecenTrialz